These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20061930)

  • 1. Omega-3 polyunsaturated fatty acids affect sirolimus exposure in kidney transplant recipients on calcineurin inhibitor-free regimen.
    Cortinovis M; Gotti E; Remuzzi G; Perico N; Cattaneo D; Baldelli S
    Transplantation; 2010 Jan; 89(1):126-7. PubMed ID: 20061930
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of sirolimus in solid organ transplantation.
    Augustine JJ; Bodziak KA; Hricik DE
    Drugs; 2007; 67(3):369-91. PubMed ID: 17335296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute drug toxicity related to drinking herbal tea in a kidney transplant recipient.
    Kwan LP; Mok MM; Ma MK; Lam MF
    Ren Fail; 2014 Mar; 36(2):309-12. PubMed ID: 24180243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced exposure to calcineurin inhibitors in renal transplantation.
    Guba M; Jauch KW
    N Engl J Med; 2008 Jun; 358(23):2518; author reply 2519-20. PubMed ID: 18525054
    [No Abstract]   [Full Text] [Related]  

  • 5. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients.
    Celik S; Doesch A; Erbel C; Blessing E; Ammon K; Koch A; Katus HA; Dengler TJ
    Transplantation; 2008 Jul; 86(2):245-50. PubMed ID: 18645486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
    Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
    Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus to replace calcineurin inhibitors? Too early yet.
    Cravedi P; Ruggenenti P; Remuzzi G
    Lancet; 2009 Apr; 373(9671):1235-6. PubMed ID: 19362662
    [No Abstract]   [Full Text] [Related]  

  • 10. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F; Andrés A; Oppenheimer F
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haplotypic arrangement in CYP3A locus is associated with side effects of proliferative signal inhibitors in renal transplant recipients.
    Bandur S; Petrasek J; Hribova P; Novotna E; Brabcova I; Viklicky O
    Transplantation; 2011 Jan; 91(1):e1-2. PubMed ID: 21441846
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia.
    Med Lett Drugs Ther; 2005 Nov; 47(1221):91. PubMed ID: 16267495
    [No Abstract]   [Full Text] [Related]  

  • 16. Sirolimus, the first mTOR inhibitor.
    Sánchez-Plumed JA; González Molina M; Alonso A; Arias M
    Nefrologia; 2006; 26 Suppl 2():21-32. PubMed ID: 17937632
    [No Abstract]   [Full Text] [Related]  

  • 17. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
    Kacar S; Gurkan A; Karaca C; Varılsuha C; Tilif S
    Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pros and the cons of mTOR inhibitors in kidney transplantation.
    Ponticelli C
    Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S; Baroletti SA
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.